Skip to main content

Advertisement

SpringerLink
Log in

Eculizumab for a catastrophic relapse in NMOSD: case report

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

  • 1 Altmetric

Abstract

Neuromyelitis optica spectrum disorders (NMOSD) are a group of inflammatory disorders of central nervous system characterized by immune-mediated demyelination and axonal damage, predominantly affecting spinal cord and optic nerves. This case report describes a 47-year-old woman with an aggressive form of seropositive NMOSD who had previously been treated with corticosteroids, plasma exchange, and cyclophosphamide. She experienced a life-threatening relapse that did not respond to conventional treatment, but ultimately showed a positive response to eculizumab. Furthermore, we describe the role of sNfL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Trebst C et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16

    Article  CAS  PubMed  Google Scholar 

  2. Jarius S et al (2023) Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. J Neurol. https://doi.org/10.1007/s00415-023-11634-0

  3. Srisupa T et al (2018) Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 20:115–121

    Article  Google Scholar 

  4. Pittock SJ et al (2019) Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614–625

    Article  CAS  PubMed  Google Scholar 

  5. Cree BAC et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet Lond Engl 394:1352–1363

    Article  CAS  Google Scholar 

  6. Yamamura T et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381:2114–2124

    Article  CAS  PubMed  Google Scholar 

  7. Wei K et al (2022) Different doses of rituximab for the therapy of neuromyelitis optica spectrum disorder: a systematic review and meta-analysis. Mult Scler Relat Disord 68:104127

    Article  CAS  PubMed  Google Scholar 

  8. Therapeutic positioning report of eculizumab (Soliris®) in neuromyelitis optica spectrum disorder 94/2023. V1. (2023)

  9. Chatterton S, Parratt JDE, Ng K (2022) Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: case report. Front Neurol 13:951423

    Article  PubMed  PubMed Central  Google Scholar 

  10. Kieseier BC, Stüve O, Dehmel T, Goebels N, Leussink VI, Mausberg AK, Ringelstein M, Turowski B, Aktas O, Antoch G, Hartung HP (2013) Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol 70(3):390–393

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroinmunology Unit, Neurology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain

    David Gorriz, Francisco Carlos Pérez-Miralles, Carlos Quintanilla-Bordás & Bonaventura Casanova

  2. Neurology Department, Hospital Universitario de la Ribera, Alzira, Spain

    Carmen Alcalá

  3. Neurology Department, Hospital Universitario Dr Peset, Valencia, Spain

    Marina Frasquet

Authors
  1. David Gorriz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francisco Carlos Pérez-Miralles
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlos Quintanilla-Bordás
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Carmen Alcalá
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Marina Frasquet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bonaventura Casanova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Gorriz.

Ethics declarations

Ethical approval

This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

The patient provided consent to publish the case report.

Competing interests

None

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gorriz, D., Pérez-Miralles, F.C., Quintanilla-Bordás, C. et al. Eculizumab for a catastrophic relapse in NMOSD: case report. Neurol Sci 45, 249–251 (2024). https://doi.org/10.1007/s10072-023-06971-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-023-06971-x

Keywords

Search

Navigation